ArticleParasites & vectors2015
Modelling control of Schistosoma haematobium infection: predictions of the long-term impact of mass drug administration in Africa.
Article in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2019Pooled it
- SCORE Operational Research on Moving toward Interruption of Schistosomiasis Transmission.The American journal of tropical medicine and hygiene · 2020Trial
- The Impact of Intensive Versus Standard Anthelminthic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Treating schistosomiasis among South African high school pupils in an endemic area, a qualitative study.BMC infectious diseases · 2018Trial
- Urogenital schistosomiasis in Cabo Delgado, northern Mozambique: baseline findings from the SCORE study.Parasites & vectors · 2018Trial
- Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: A SCORE project in Northern Mozambique.PLoS neglected tropical diseases · 2017Trial
- Individual and spatial heterogeneity of praziquantel efficacy against Schistosoma mansoni within the context of repeated mass drug administration.Parasites & vectors · 2026Article
- Host genetic background influences the severity of disease in Schistosoma haematobium infections.Parasite (Paris, France) · 2026Article
- Development of a dynamical model to enhance understanding of epidemiology of schistosomiasis in school-aged-children.Scientific reports · 2025Article
- Molluscicidal and Schistosomicidal Activities of 2-(1Pharmaceuticals (Basel, Switzerland) · 2025Article
- Knowledge, Perceptions, Challenges and opportunities in achieving sustainable coverage of mass drug administration towards the control and elimination of Schistosomiasis and Soil Transmitted Helminths in hard-to-reach communities of Ghana.PLoS neglected tropical diseases · 2024Article
- Revisiting the impact of Schistosoma mansoni regulating mechanisms on transmission dynamics using SchiSTOP, a novel modelling framework.PLoS neglected tropical diseases · 2024Article
- Urogenital schistosomiasis among adult male population in an endemic area of southern Tanzania: a descriptive cross-sectional study.BMJ open · 2024Article
- Improved Assessment ofOpen forum infectious diseases · 2024Article
- Association between polymorphisms of IL4, IL13, IL10, STAT6 and IFNG genes, cytokines and immunoglobulin E levels with high burden of Schistosoma mansoni in children from schistosomiasis endemic areas of Cameroon.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2023Article
- Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo.Nature communications · 2023Article
- Fine-scale mapping of Schistosoma mansoni infections and infection intensities in sub-districts of Makenene in the Centre region of Cameroon.PLoS neglected tropical diseases · 2022Article
- The Road to Elimination: Current State of Schistosomiasis Research and Progress Towards the End Game.Frontiers in immunology · 2022Review
- Challenges of using modelling evidence in the visceral leishmaniasis elimination programme in India.PLOS global public health · 2022Article
- Application of Schistosomiasis Consortium for Operational Research and Evaluation Study Findings to Refine Predictive Modeling ofThe American journal of tropical medicine and hygiene · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective control of schistosomiasis remains a challenging problem for endemic areas of the world. Given knowledge of the biology of transmission and past experience with mass drug administration (MDA) programs, it is important to critically evaluate the likelihood that MDA programs will achieve substantial reductions in Schistosoma prevalence. In implementing the World Health Organization Roadmap for Neglected Tropical Diseases it would useful for policymaking to model projections of the status of Schistosoma control in MDA-treated areas in the next 5-10 years.
methodsCalibrated mathematical models were used to project the effects of different frequency and coverage of MDA for schistosomiasis haematobia control in present-day endemic communities, taking into account uncertainties of parasite biology and input data. The modeling approach in this analysis was the Stratified Worm Burden model developed in our earlier works, calibrated using data from longitudinal S. haematobium control trials in Kenya.
resultsModel-based simulations of MDA control in typical low-risk and higher-risk communities indicated that infection prevalence can be substantially reduced within 10 years only when there is a high degree of community participation (>70 %) with at least annual MDA. Significant risk for re-emergence of infection remains if MDA is suspended.
conclusionsIn a stable (stationary) ecosystem, Schistosoma reproduction and transmission are sufficiently robust that the process of human infection continues, even under pressure from aggressive MDA. MDA alone is unlikely to interrupt transmission, and once mass treatment is suspended, the prevalence of human infection is likely to rebound to pre-control levels over a period of 25-30 years. MDA success in achieving very low levels of infection prevalence is highly dependent on treatment coverage and frequency within the local human population, and requires that both adults and children be included in drug delivery coverage. Ultimately, supplemental snail control and significant improvements in sanitation will be required to achieve full control of schistosomiasis by elimination of ongoing Schistosoma transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.